Title: County by county estimation of possible deaths averted, infections averted, and cost savings of overdose prevention health centers in the United States from January 2020-June 2025.

Authors: Mike Sportiello, MD, PhD[1], Rohith Palli MD, PhD [2]

1. Emory University School of Medicine Department of Medicine. 49 Jesse Hill Dr. SE, Suite 491, Atlanta, GA 30303. Msporti@emory.edu. Corresponding author.
2. University of Washington Department of Biomedical Informatics and Medical Education. Box 358047. 850 Republican St. Seattle, WA 98195.

Abstract

Overdose prevention health centers (OPHCs), also known as overdose prevention centers or safe injection facilities (SIFs), are an evidence-based strategy for people to use drugs in an environment monitored by health care professionals with access to drug use education, sterile supplies, and referral infrastructure to access higher levels of medical and behavioral health resources. Though still illegal under federal law throughout the United States, many legal or quasi-legal (including some in the United States) have operated since the 1980s. Using CDC overdose deaths and United States Census Bureau population data, we estimate 1,325 deaths could have been averted between 2020 and June 2025 if 1 out of 400 injections had taken place at an OPHC. At this rate, 26 HIV transmissions and 5,723 Hepatitis C Virus transmissions would have been averted. Over $1.8 billion in discounted lifetime costs to treat those infections could have been saved. This data supports OPHCs as one viable public health intervention to avert deaths and avoid infections. Furthermore, a web application was created to assist users explore this analysis, data visualizations, and even alter model assumptions, including variables like what percent of injections occur at an OPHC.

Introduction

Overdose prevention health centers (OPHCs), also known as overdose prevention centers or safe injection centers, are an evidence-based strategy for people to use drugs in an environment monitored by health care professionals with access to drug use education, sterile supplies, and referral infrastructure to access higher levels of medical and behavioral health resources. Though still illegal under federal law throughout the United States, many legal or quasi-legal (including some in the United States) have operated since the 1980s (Beletsky et al., 2018). Since this time, there have been reported overdoses, but no reported deaths in this supervised health care setting, as naloxone, an opioid overdose reversal agent as well as access to respiratory support such as supplemental oxygen or bag-mask ventilation is readily available. Many other studies have focused on assessing the impact of an OPHC in their community (Irwin et al., 2016), but no study has modeled the likely impact across the country. Notably, many studies have focused on local areas in Canada and have shown reduction in deaths due to opioid overdose (Irvine et al., 2019; Pauly et al., 2020; Rammohan et al., 2024; Scheidell et al., 2024), and a recent meta-analysis demonstrated cost effectiveness of OPHC across North American cities (Behrends et al., 2024). In this manuscript, we analyze how many deaths averted, infections averted, and the cost savings accrued had the county adopted OPHCs during this time and present a web application for users to explore the data and alter model assumptions, with constraints.

Methods

Drug overdose deaths by month per county were accessed from the National Center for Health Statistics from 2020-June 2025. Population and age data were downloaded from the United States Census Bureau. County names were standardized. For this analysis, we estimated 1.5% of adults were people who injected drugs (PWID) per others' work (Bradley et al., 2023). For each PWID, we estimated 508.8 injections per year, or just under 1.5 injections per day per other's work (Bradley et al., 2023).

Deaths averted

Deaths averted was calculated by assuming the total number of injections stayed constant. Secondly, we assumed that deaths cannot occur after an injection in the OPHC, as no overdose death has ever occurred in an OPHC. The *injections that would occur at OPHC* was calculated by modeling 0.25%, 0.5%, 0.75%, or 1% of injections taking place at the OPHC. This led to the following calculation:

$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * Overdose\ deaths = Deaths\ averted$$

With the fraction on the left simplifying to the frequency of total injections in the OPHC, multiplied by the number of deaths. If all the injections took place at the OPHC, the leftmost fraction would simplify to 1 and all deaths would be averted. If none did, the whole left term would simplify to 0 and no deaths would be averted.

HCV transmissions averted

Hepatitis C virus (HCV) is a highly transmissible virus in the setting of shared needle use, leading to significant morbidity, mortality, and health expenditures. While curative therapy now exists, it is expensive and requires weeks-long adherence, which is difficult for

many who inject drugs as they are disproportionately housing insecure and have varied of trust in professional medical infrastructure. Similar to deaths averted, due to the supply of sterile drug use equipment including needles and cottons, transmission of HCV has never been documented at an OPHC. Natural incidence of HCV within PWID varies widely, with studies with varying from 0.51 to 47 per 100 person years. For this analysis, we used a lower-end estimate of 10 per 100 person years (Gutfraind et al., 2015), leading to the following equation:

$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HCV\ incidence = HCV\ transmissions\ averted$$

HIV transmissions averted

Though the vast majority of HIV is not transmitted through injection drug use, it is still a meaningful target of HIV transmission prevention efforts. Others have calculated the incidence of HIV transmission in groups of people who inject drugs, stratifying their use as low, medium, and high risk depending on factors including how often they share needles with people they know and alternatively with strangers (Jarlais et al., 2022). Using these incidences, we calculated HIV transmissions averted with the following equations:

$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HIV\ incidence\ [low\ risk]$$

$$= HIV\ transmissions\ averted$$

$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HIV\ incidence\ [medium\ risk]$$

$$= HIV\ transmissions\ averted$$

$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HIV\ incidence\ [high\ risk]$$

$$= HIV\ transmissions\ averted$$

Financial impact

Substantial health care dollars are spent treating preventable diseases. Infectious diseases are a particularly good target given how easily they can be prevented with appropriate education and low-cost materials. Others have estimated the discounted lifetime cost of an HIV infection to be $448,095 (after adjusting for inflation) (Schackman et al., 2015). We calculated the discounted lifetime cost of an HIV infection with the following equation:

$$\$448{,}095\ * averted\ HIV\ transmission = Discounted\ cost\ of\ an\ averted\ HIV\ infection$$

Similar work has been done to calculate the discounted lifetime cost of HCV, calculated to $339,968 (after adjusting for inflation) (Liu et al., 2016).

$$\$339{,}968 * averted\ HCV\ transmission = Discounted\ cost\ of\ an\ averted\ HCV\ infection$$

Finally, we calculated the total statistical costs of the lives to those who died from overdose, using the dollar mount the Federal Emergency Medical Agency $7,500,000 uses for their calculations, giving the following equation:

$$\$7{,}500{,}000 * Averted\ deaths = Statistical\ costs\ of\ deaths\ averted$$

Web application

A web application was created using the Shiny infrastructure and written R. All code is free and open source and can be found here: https://github.com/sportiellomike/OPHC-shiny. The most up to date version of the web app itself can be found here: https://sportiellomike.shinyapps.io/OPHC-shiny/. Minimal assistance in coding was

provided by generative artificial intelligence. Anthropic's claude-3.5-sonnet model was used. All additions provided by AI were manually checked at the time of coding for both function and syntax. Generative AI was not utilized to create or manipulate any figure.

Results

Analytic results

Deaths averted depends on what percentage of injections occur at the OPHC (Table 1). At the low end assuming 0.25% of injections occurred at OPHCs (1 injection out of 400, or one injection every 287 days [400/(508.8/365)]) per PWID, 1,325 deaths would have been averted. At the higher end of 1% of injections occurring at the OPHC, over 5,300 deaths could have been averted.

Table 1: Summary table of results

Percent injections at OPHC	0.25%	0.5%	0.75%	1%
Deaths averted	1325.12	2650.24	3975.36	5300.48
HCV averted	5722.99	11445.98	17168.98	22891.97
HIV-low averted	11.45	22.89	34.34	45.78
HIV-medium averted	26.33	52.65	78.98	105.30
HIV-high averted	32.05	64.10	96.15	128.20
Discounted lifetime cost infections	1.84E+09	3.68E+09	5.53E+09	7.37E+09
Cost of life	9.94E+09	1.99E+10	2.98E+10	3.98E+10
Total costs	1.18E+10	2.36E+10	3.53E+10	4.71E+10
Total costs (billions)	11.78	23.56	35.34	47.12

HCV infections averted range from just under 5,723 to just under 22,892 (Table 1). Dozens of HIV transmissions could have been averted (Table 1). Tens of billions in cost would have been averted with higher use, from relatively low rates of usage of OPHCs (Table 1).

Even if OPHCs were only instituted in the top 50 counties with the most PWID (Table 2) or the top 50 deaths per capita (Table 3), a substantial impact would be seen. A list of these counties can be found in supplementary Tables 1 and 2 respectively.

Table 2: Results for 50 most populous counties

Percent injections at OPHC	0.25%	0.5%	0.75%	1%
Deaths averted	403.75	807.49	1211.24	1614.98
HCV averted	1738.93	3477.85	5216.78	6955.71
HIV-low averted	3.48	6.96	10.43	13.91
HIV-medium averted	8.00	16.00	24.00	32.00
HIV-high averted	9.74	19.48	29.21	38.95
Discounted lifetime cost of infections	5.60E+08	1.12E+09	1.68E+09	2.24E+09
Cost of life	3.03E+09	6.06E+09	9.08E+09	1.21E+10
Total costs	3.59E+09	7.18E+09	1.08E+10	1.44E+10
Total costs (billions)	3.59	7.18	10.76	14.35

Table 3: Results for 50 counties with most deaths per capita

Percent injections at OPHC	0.25%	0.5%	0.75%	1%
Deaths averted	53.28	106.56	159.84	213.12
HCV averted	83.82	167.64	251.46	335.28
HIV-low averted	0.17	0.34	0.50	0.67
HIV-medium averted	0.39	0.77	1.16	1.54
HIV-high averted	0.47	0.94	1.41	1.88
Discounted lifetime cost of infections	2.70E+07	5.40E+07	8.09E+07	1.08E+08
Cost of life	4.00E+08	7.99E+08	1.20E+09	1.60E+09
Total costs	4.27E+08	8.53E+08	1.28E+09	1.71E+09
Total costs (billions)	0.43	0.85	1.28	1.71

Web application

These results are presented here in table format, but it may be of use to users to visualize results on a per-state or per-county basis. To assist in this process, a free and open-source interactive web application was constructed for users to investigate individual counties and create color-coded maps and tables with additional parameters not reported here (discounted costs broken down between HIV and HCV, for example) specific to their

applications (Figure 1). The most up to date version can always be found at: https://sportiellomike.shinyapps.io/OPHC-shiny/.



Figure 1: OPHC Data Explorer Web Application

Discussion

While it is difficult to estimate the rates of use of OPHCs by those injecting, this study supplies a framework to assist in estimating their impact on deaths, infections, and cost savings. Even at very low rates of use, assuming one out of every 400 injections occurs at OPHCs, hundreds of deaths and thousands of HCV transmissions would have been averted over the period studied. Dozens of HIV transmissions would have been averted. This study also analyzes the impact on if the 50 most populous (Table 2) or the 50 counties with the most deaths (Table 3) were to have constructed an OPHC, a potentially more

realistic and cost-effective strategy. This study makes no precise estimation on future deaths averted, infections averted, or costs, though it is likely to be favorable as it was during this studied time period.

Importantly, this analysis does not include secondary benefits of OPHCs like the association of people voluntarily joining detoxification programs, methadone initiation programs, or long-term addiction treatment initiation (Wood et al., 2007). It also doesn't include benefits that education has such as decreasing the rates of needle sharing (Kerr et al., 2005). Lastly, this analysis doesn't include the benefits of secondary social supports unrelated to drug use, including housing support, food support, or other programs.

This analysis doesn't include any secondary detriments of OPHCs, though it should be noted that most of those of concern (increase in overdoses, increase in new-onset illicit injection drug use) have not been borne out by studies that that have actually measured these important issues of concern. One important aspect not included in this analysis is the cost to build and maintain these OPHCs, which would require both direct costs of salaries of health and social workers, as well as maintaining these buildings over time. Another drawback of this analysis is that its precision is not forward facing: we do not make estimates on the impact of future OPHCs, just that OPHC construction would have had large benefits in the past. New and currently ongoing interventions to reduce deaths and infections, even without decreasing the rates of injection, would mitigate some of the greatest benefits of OPHCs.

Another caveat of this study is the difficulty in estimating how many injections would have occurred at the OPHCs had they been constructed. Likely, OPHC use would

173 vary based on a particular area's infrastructure and culture in addition to the capacity of
174 the OPHC itself. Which drugs used by whom in what setting with what relationship to the
175 healthcare and law enforcement institutions varies widely even within the same city and
176 sometimes the same neighborhood. A rate of 1/400 injections occurring at the OPHC, for
177 example, would more likely be achieved by some using the OPHC far more frequently than
178 that rate and most using it far less frequently than that rate. No study has used an
179 evidence-based estimate for likely uptake, so we present here a conservative and broad
180 range of 0.25%-1% of injections occurring at an OPHC.

181 Overall, these data support the broad construction and initiation of OPHCs as a
182 measure to prevent the mortality and morbidity associated with injection drug use. Our
183 limitations highlight the importance of more empirical work in the area to enable more even
184 more precise estimates.

References

Behrends, C. N., Leff, J. A., Lowry, W., Li, J. M., Onuoha, E. N., Fardone, E., Bayoumi, A. M., McCollister, K. E., Murphy, S. M., & Schackman, B. R. (2024). Economic Evaluations of Establishing Opioid Overdose Prevention Centers in 12 North American Cities: A Systematic Review. *Value Health*, *27*(5), 655–669. https://doi.org/10.1016/j.jval.2024.02.004

Beletsky, L., Baker, P., Arredondo, J., Emuka, A., Goodman-Meza, D., Medina-Mora, M. E., Werb, D., Davidson, P., Amon, J. J., Strathdee, S., & Magis-Rodriguez, C. (2018). The global health and equity imperative for safe consumption facilities. *Lancet*, *392*(10147), 553–554. https://doi.org/10.1016/S0140-6736(18)31469-7

Bradley, H., Hall, E. W., Asher, A., Furukawa, N. W., Jones, C. M., Shealey, J., Buchacz, K., Handanagic, S., Crepaz, N., & Rosenberg, E. S. (2023). Estimated Number of People Who Inject Drugs in the United States. *Clin Infect Dis*, *76*(1), 96–102. https://doi.org/10.1093/cid/ciac543

Gutfraind, A., Boodram, B., Prachand, N., Hailegiorgis, A., Dahari, H., & Major, M. E. (2015). Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections. *PLoS One*, *10*(9), e0137993. https://doi.org/10.1371/journal.pone.0137993

Irvine, M. A., Kuo, M., Buxton, J. A., Balshaw, R., Otterstatter, M., Macdougall, L., Milloy, M. J., Bharmal, A., Henry, B., Tyndall, M., Coombs, D., & Gilbert, M. (2019). Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic. *Addiction*, *114*(9), 1602–1613. https://doi.org/10.1111/add.14664

Irwin, A., Jozaghi, A., Bluthenthal, R. N., & Kral, A. H. (2016). A Cost-Benefit Analysis of a Potential Supervised Injection Facility in San Francisco, California, USA. *Journal of Drug Issues*, *47*(2). https://doi.org/https://doi.org/10.1177/0022042616679829

Jarlais, D. D., Bobashev, G., Feelemyer, J., & McKnight, C. (2022). Modeling HIV transmission among persons who inject drugs (PWID) at the "End of the HIV Epidemic" and during the COVID-19 pandemic. *Drug Alcohol Depend*, *238*, 109573. https://doi.org/10.1016/j.drugalcdep.2022.109573

Kerr, T., Tyndall, M., Li, K., Montaner, J., & Wood, E. (2005). Safer injection facility use and syringe sharing in injection drug users. *Lancet*, *366*(9482), 316–318. https://doi.org/10.1016/S0140-6736(05)66475-6

Liu, S., Barnett, P. G., Holodniy, M., Lo, J., Joyce, V. R., Gidwani, R., Asch, S. M., Owens, D. K., & Goldhaber-Fiebert, J. D. (2016). Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in non-VA and VA Populations. *MDM Policy Pract*, *1*(1). https://doi.org/10.1177/2381468316671946

Pauly, B., Wallace, B., Pagan, F., Phillips, J., Wilson, M., Hobbs, H., & Connolly, J. (2020). Impact of overdose prevention sites during a public health emergency in Victoria, Canada. *PLoS One*, *15*(5), e0229208. https://doi.org/10.1371/journal.pone.0229208

Rammohan, I., Gaines, T., Scheim, A., Bayoumi, A., & Werb, D. (2024). Overdose mortality incidence and supervised consumption services in Toronto, Canada: an ecological study and spatial analysis. *Lancet Public Health*, *9*(2), e79–e87. https://doi.org/10.1016/S2468-2667(23)00300-6

228 Schackman, B. R., Fleishman, J. A., Su, A. E., Berkowitz, B. K., Moore, R. D., Walensky, R. P.,
229 Becker, J. E., Voss, C., Paltiel, A. D., Weinstein, M. C., Freedberg, K. A., Gebo, K. A., &
230 Losina, E. (2015). The lifetime medical cost savings from preventing HIV in the United
231 States. *Med Care*, *53*(4), 293–301. https://doi.org/10.1097/MLR.0000000000000308
232 Scheidell, J. D., Townsend, T. N., Zhou, Q., Manandhar-Sasaki, P., Rodriguez-Santana, R., Jenkins,
233 M., Buchelli, M., Charles, D. L., Frechette, J. M., Su, J. I., & Braithwaite, R. S. (2024).
234 Reducing overdose deaths among persons with opioid use disorder in connecticut. *Harm*
235 *Reduct J*, *21*(1), 103. https://doi.org/10.1186/s12954-024-01026-6
236 Wood, E., Tyndall, M. W., Zhang, R., Montaner, J. S., & Kerr, T. (2007). Rate of detoxification
237 service use and its impact among a cohort of supervised injecting facility users.
238 *Addiction*, *102*(6), 916–919. https://doi.org/10.1111/j.1360-0443.2007.01818.x
239

240

Counties with highest number of PWID
California-Los Angeles County
Illinois-Cook County
Texas-Harris County
Arizona-Maricopa County
California-San Diego County
California-Orange County
Florida-Miami-Dade County
New York-Kings County
Texas-Dallas County
New York-Queens County
California-Riverside County
Washington-King County
Nevada-Clark County
California-San Bernardino County
Texas-Tarrant County
Florida-Broward County
Texas-Bexar County
California-Santa Clara County
New York-New York County
Michigan-Wayne County
California-Alameda County
Massachusetts-Middlesex County
Pennsylvania-Philadelphia County
Florida-Palm Beach County
California-Sacramento County
New York-Suffolk County
Florida-Hillsborough County
Florida-Orange County
New York-Nassau County
New York-Bronx County
Texas-Travis County
Ohio-Franklin County
Michigan-Oakland County
Pennsylvania-Allegheny County
Minnesota-Hennepin County
Ohio-Cuyahoga County
California-Contra Costa County
North Carolina-Wake County

Virginia-Fairfax County
Utah-Salt Lake County
North Carolina-Mecklenburg County
Georgia-Fulton County
Arizona-Pima County
Texas-Collin County
Maryland-Montgomery County
Florida-Pinellas County
Hawaii-Honolulu County
New York-Westchester County
Florida-Duval County
Missouri-St. Louis County

Supplementary table 1: Counties with highest number of PWID

Counties with highest deaths per capita
Texas-Borden County
New Mexico-Rio Arriba County
Kentucky-Lee County
Nebraska-Logan County
Texas-Kent County
New Mexico-Taos County
Alaska-Lake and Peninsula County
California-Lake County
Kentucky-Powell County
West Virginia-Logan County
Maryland-Baltimore (city) County
West Virginia-Cabell County
Kansas-Greeley County
Kentucky-Estill County
West Virginia-Lincoln County
Kentucky-Knott County
Kentucky-Breathitt County
West Virginia-Mercer County
California-Del Norte County
Kentucky-Boyd County
Arizona-La Paz County
West Virginia-Mingo County

Texas-Karnes County
Tennessee-Roane County
Texas-Irion County
Louisiana-Washington County
Washington-Okanogan County
Alaska-Anchorage County
Kentucky-Clay County
Tennessee-Morgan County
Tennessee-DeKalb County
Washington-Grays Harbor County
West Virginia-McDowell County
Alabama-Walker County
Virginia-Buchanan County
Kentucky-Rockcastle County
Missouri-St. Louis (city) County
Texas-Dickens County
North Dakota-Golden Valley County
California-Butte County
California-Alpine County
Tennessee-Cocke County
New Mexico-Santa Fe County
Nebraska-Garden County
Washington-Spokane County
Kentucky-Harlan County
Colorado-Cheyenne County
Pennsylvania-Philadelphia County
Tennessee-Campbell County
Utah-Piute County

Supplementary table 2: Counties with highest deaths per capita